Induction and Donor Specific Antibodies in Low Immunologic Risk Kidney Transplant Recipients.


Journal

Kidney360
ISSN: 2641-7650
Titre abrégé: Kidney360
Pays: United States
ID NLM: 101766381

Informations de publication

Date de publication:
31 12 2020
Historique:
received: 13 01 2020
accepted: 01 10 2020
entrez: 4 4 2022
pubmed: 1 10 2020
medline: 8 4 2022
Statut: epublish

Résumé

Optimal induction for patients without pretransplant donor-specific antibodies (DSAs) is poorly defined. The goal of this study was to compare the incidence of A retrospective chart review was performed, identifying 782 patients with a negative VXM who underwent kidney transplantation at a single, high-volume institution between January 2013 and May 2017. Kaplan-Meier analysis was used to assess the incidence of dnDSA and allograft survival between induction therapies in this group. dnDSA is defined as the development of new post-transplant DSA, at any MFI level. Induction therapy included alemtuzumab ( In summary, alemtuzumab was associated with a higher rate of dnDSA development in patients with a negative VXM; however, this finding was not associated with rejection or graft failure.

Sections du résumé

Background
Optimal induction for patients without pretransplant donor-specific antibodies (DSAs) is poorly defined. The goal of this study was to compare the incidence of
Methods
A retrospective chart review was performed, identifying 782 patients with a negative VXM who underwent kidney transplantation at a single, high-volume institution between January 2013 and May 2017. Kaplan-Meier analysis was used to assess the incidence of dnDSA and allograft survival between induction therapies in this group. dnDSA is defined as the development of new post-transplant DSA, at any MFI level.
Results
Induction therapy included alemtuzumab (
Conclusions
In summary, alemtuzumab was associated with a higher rate of dnDSA development in patients with a negative VXM; however, this finding was not associated with rejection or graft failure.

Identifiants

pubmed: 35372884
doi: 10.34067/KID.0000122020
pii: K3602020000012
pmc: PMC8815535
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1407-1418

Informations de copyright

Copyright © 2020 by the American Society of Nephrology.

Déclaration de conflit d'intérêts

All authors have nothing to disclose.

Références

Transplantation. 2002 Oct 27;74(8):1192-4
pubmed: 12438971
Transplantation. 2019 Aug;103(8):1722-1729
pubmed: 30507740
Transplantation. 2003 Sep 15;76(5):798-802
pubmed: 14501856
Nat Rev Neurol. 2013 Mar;9(3):125-6
pubmed: 23358486
Transplant Proc. 2010 Jun;42(5):1395-400
pubmed: 20620442
N Engl J Med. 2008 Oct 16;359(16):1736-8
pubmed: 18923181
Transplantation. 2003 Apr 15;75(7):1034-40
pubmed: 12698094
Transplant Direct. 2017 Oct 27;3(12):e227
pubmed: 29536028
Am J Transplant. 2002 Jan;2(1):48-56
pubmed: 12095056
Transplantation. 2001 Dec 27;72(12):1915-9
pubmed: 11773888
Transplantation. 2014 Mar 27;97(6):612-7
pubmed: 24531846
Am J Transplant. 2018 Jan;18 Suppl 1:18-113
pubmed: 29292608
Am J Transplant. 2003 Jun;3(6):722-30
pubmed: 12780564
N Engl J Med. 2006 Nov 9;355(19):1967-77
pubmed: 17093248
Transplantation. 2003 Mar 27;75(6):844-51
pubmed: 12660513
Kidney Int. 2013 Jun;83(6):1185-92
pubmed: 23447068
Am J Transplant. 2007 Feb;7(2):408-15
pubmed: 17229080
Am J Transplant. 2012 May;12(5):1157-67
pubmed: 22429309
Am J Transplant. 2003 Jun;3(6):665-73
pubmed: 12780557
Int J Mol Sci. 2015 Jul 20;16(7):16414-39
pubmed: 26204829
Pharmacotherapy. 2016 Jul;36(7):823-9
pubmed: 27265620
Ann Surg. 2017 Dec;266(6):1084-1090
pubmed: 27655240
Transpl Int. 2013 Jul;26(7):662-72
pubmed: 23279211
J Am Soc Nephrol. 2017 Jul;28(7):2188-2200
pubmed: 28320767
Transplantation. 2011 Jul 15;92(1):12-7
pubmed: 21512428
Am J Transplant. 2017 Dec;17(12):3210-3218
pubmed: 28805293
Transplantation. 2010 Dec 27;90(12):1511-5
pubmed: 21057388
J Clin Immunol. 2010 Jan;30(1):99-105
pubmed: 19763798
Am J Transplant. 2007 Apr;7(4):864-71
pubmed: 17391129
Transplant Rev (Orlando). 2013 Oct;27(4):108-11
pubmed: 23958238
JAMA. 2011 Nov 2;306(17):1891-901
pubmed: 22045767
J Immunol. 2013 Sep 1;191(5):2818-28
pubmed: 23913968
Am J Transplant. 2005 Oct;5(10):2539-48
pubmed: 16162205
Am J Transplant. 2004 Jan;4(1):87-93
pubmed: 14678038

Auteurs

Natalie M Bath (NM)

Division of Transplant, Department of Surgery, University of Wisconsin Hospital and Clinics, Madison, Wisconsin.

Arjang Djamali (A)

Division of Nephrology, Department of Medicine, University of Wisconsin Hospital and Clinics, Madison, Wisconsin.

Sandesh Parajuli (S)

Division of Nephrology, Department of Medicine, University of Wisconsin Hospital and Clinics, Madison, Wisconsin.

Didier Mandelbrot (D)

Division of Nephrology, Department of Medicine, University of Wisconsin Hospital and Clinics, Madison, Wisconsin.

Glen Leverson (G)

Department of Surgery, University of Wisconsin Hospital and Clinics, Madison, Wisconsin.

Luis Hidalgo (L)

Division of Transplant, Department of Surgery, University of Wisconsin Hospital and Clinics, Madison, Wisconsin.

Thomas Ellis (T)

Department of Pathology and Laboratory Medicine, University of Wisconsin Hospital and Clinics, Madison, Wisconsin.

Jillian L Descourouez (JL)

Division of Transplant, Department of Surgery, University of Wisconsin Hospital and Clinics, Madison, Wisconsin.

Margaret R Jorgenson (MR)

Division of Transplant, Department of Surgery, University of Wisconsin Hospital and Clinics, Madison, Wisconsin.

Dave Hager (D)

Division of Transplant, Department of Surgery, University of Wisconsin Hospital and Clinics, Madison, Wisconsin.

Dixon B Kaufman (DB)

Division of Transplant, Department of Surgery, University of Wisconsin Hospital and Clinics, Madison, Wisconsin.

Robert R Redfield (RR)

Division of Transplant, Department of Surgery, University of Wisconsin Hospital and Clinics, Madison, Wisconsin.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH